$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000162828018013909 Filed on November 07, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$1.678M	$1.587M	$6.892M
YoY Change	-33.78%	-76.97%	790.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.930M	$2.630M	$3.660M
YoY Change	67.51%	-28.14%	-1.61%
% of Gross Profit
Research & Development	$11.06M	$16.57M	$15.54M
YoY Change	-37.93%	6.62%	-1.28%
% of Gross Profit
Depreciation & Amortization	$500.0K	$497.0K	$593.0K
YoY Change	-19.35%	-16.19%	103.78%
% of Gross Profit
Operating Expenses	$17.50M	$34.01M	$19.79M
YoY Change	-20.42%	71.88%	0.2%
Operating Profit	-$16.90M	-$32.43M	-$12.90M
YoY Change	-71.94%	151.42%	-32.03%
Interest Expense	-$2.380M	$0.00	$76.00K
YoY Change	-1233.33%	-100.0%
% of Operating Profit
Other Income/Expense, Net		$3.671M	$1.297M
YoY Change		183.04%	-309.19%
Pretax Income	-$18.25M	-$28.76M	-$11.60M
YoY Change	-69.71%	147.89%	-40.8%
Income Tax	$0.00	-$4.282M	$0.00
% Of Pretax Income
Net Earnings	-$18.25M	-$24.47M	-$11.60M
YoY Change	-49.21%	110.97%	-40.8%
Net Earnings / Revenue	-1087.54%	-1542.09%	-168.31%
Basic Earnings Per Share	-$0.38	-$0.49
Diluted Earnings Per Share	-$0.38	-$0.49	-$211.4K
COMMON SHARES
Basic Shares Outstanding	55.48M shares	55.40M shares	55.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$124.6M	$142.0M	$88.20M
YoY Change	-1.42%	61.0%	-41.08%
Cash & Equivalents	$36.94M	$21.93M	$15.23M
Short-Term Investments	$87.70M	$120.1M	$73.00M
Other Short-Term Assets	$2.800M	$1.100M	$1.500M
YoY Change	33.33%	-26.67%	0.0%
Inventory
Prepaid Expenses
Receivables	$1.431M	$538.0K	$846.0K
Other Receivables	$400.0K	$400.0K	$100.0K
Total Short-Term Assets	$129.2M	$144.0M	$90.81M
YoY Change	-0.11%	58.6%	-40.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.15M	$10.42M	$12.62M
YoY Change	-16.73%	-17.44%	208.91%
Goodwill	$22.47M	$22.47M	$24.36M
YoY Change	-7.77%	-7.77%	-85.01%
Intangibles	$43.84M	$43.84M	$99.45M
YoY Change	-25.25%	-55.92%	-49.34%
Long-Term Investments	$22.22M	$24.67M
YoY Change
Other Assets	$0.00	$0.00	$12.60M
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$98.68M	$101.4M	$149.0M
YoY Change	-8.46%	-31.97%	-58.94%
TOTAL ASSETS
Total Short-Term Assets	$129.2M	$144.0M	$90.81M
Total Long-Term Assets	$98.68M	$101.4M	$149.0M
Total Assets	$227.9M	$245.4M	$239.8M
YoY Change	-3.9%	2.32%	-53.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.200M	$3.100M	$2.300M
YoY Change	60.0%	34.78%	9.52%
Accrued Expenses	$7.600M	$6.200M	$4.100M
YoY Change	-11.63%	51.22%	-14.58%
Deferred Revenue	$0.00	$649.0K
YoY Change	-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.24M	$12.67M	$8.235M
YoY Change	-23.16%	53.83%	-1.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$12.00M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$3.800M	$4.800M	$11.00M
YoY Change	-65.77%	-56.36%	32.53%
Total Long-Term Liabilities	$3.800M	$4.800M	$23.00M
YoY Change	-83.55%	-79.13%	177.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.24M	$12.67M	$8.235M
Total Long-Term Liabilities	$3.800M	$4.800M	$23.00M
Total Liabilities	$27.67M	$30.15M	$72.45M
YoY Change	-49.4%	-58.39%	-26.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$805.2M	-$784.3M	-$699.6M
YoY Change	9.1%	12.11%	61.78%
Common Stock	$879.4M	$878.8M	$876.0M
YoY Change	0.38%	0.31%	1.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$200.2M	$215.3M	$167.4M
YoY Change
Total Liabilities & Shareholders Equity	$227.9M	$245.4M	$239.8M
YoY Change	-3.9%	2.32%	-53.4%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$18.25M	-$24.47M	-$11.60M
YoY Change	-49.21%	110.97%	-40.8%
Depreciation, Depletion And Amortization	$500.0K	$497.0K	$593.0K
YoY Change	-19.35%	-16.19%	103.78%
Cash From Operating Activities	-$17.08M	-$13.20M	-$15.68M
YoY Change	65.18%	-15.79%	6.58%
INVESTING ACTIVITIES
Capital Expenditures	-$230.0K	$237.0K	$538.0K
YoY Change	27.78%	-55.95%	220.24%
Acquisitions
YoY Change
Other Investing Activities	$45.01M	$12.01M	$5.840M
YoY Change	4901.11%	105.65%	-922.54%
Cash From Investing Activities	$44.78M	$24.38M	$5.305M
YoY Change	6207.04%	359.53%	-702.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	110.0K	$435.0K	$61.00K
YoY Change	-99.78%	613.11%	-19.74%
NET CHANGE
Cash From Operating Activities	-17.08M	-$13.20M	-$15.68M
Cash From Investing Activities	44.78M	$24.38M	$5.305M
Cash From Financing Activities	110.0K	$435.0K	$61.00K
Net Change In Cash	27.81M	$11.74M	-$8.987M
YoY Change	-29.18%	-230.63%	-42.08%
FREE CASH FLOW
Cash From Operating Activities	-$17.08M	-$13.20M	-$15.68M
Capital Expenditures	-$230.0K	$237.0K	$538.0K
Free Cash Flow	-$16.85M	-$13.44M	-$16.22M
YoY Change	65.85%	-17.12%	8.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2893000	USD
CY2018Q3	abus	Accrued Payroll Current AccruedPayrollCurrent	514000	USD
CY2017Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	4937000	USD
CY2018Q3	abus	Accrued Research And Development AccruedResearchAndDevelopment	4178000	USD
CY2018Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-504000	USD
CY2018Q2	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-34000	USD
CY2018Q3	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-407000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2848000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
	abus	Employee Stock Options Liability Classified Exercised During Period EmployeeStockOptionsLiabilityClassifiedExercisedDuringPeriod	103000	USD
CY2017Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	1239000	USD
CY2018Q3	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	2738000	USD
CY2017Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	197000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	1146000	USD
CY2018Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-5608000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-6263000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9256000	CAD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2017	abus	Restricted Investment Term RestrictedInvestmentTerm	P2Y
	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2018Q3	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55477235	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10646000	USD
CY2018Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8511000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1987000	USD
CY2018Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3075000	USD
CY2017Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	402000	USD
CY2018Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	538000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	402000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	538000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	429000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	722000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12671000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6392000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48185000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48197000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42840000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45500000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1510000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1862000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1658000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	135000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5339714	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24211817	shares
CY2017Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14811000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14811000	USD
CY2017Q4	us-gaap	Assets Assets	237161000	USD
CY2018Q3	us-gaap	Assets Assets	245418000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	129366000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	144025000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	197000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1146000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5608000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6263000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9065000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10211000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10424000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4161000	USD
CY2017Q3	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6000	USD
CY2018Q3	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54292000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21933000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23413000	USD
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55472319	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	876108000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24212000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15225000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66893000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10193000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21933000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8987000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8188000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11740000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44960000	USD
CY2017Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2018Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55060662	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55472319	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55060662	shares
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	878805000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11600000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48482000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24485000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38823000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2742000	USD
CY2018Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	649000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2742000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	649000	USD
CY2017Q3	us-gaap	Contribution Of Property ContributionOfProperty	0	USD
	us-gaap	Contribution Of Property ContributionOfProperty	0	USD
CY2018Q3	us-gaap	Contribution Of Property ContributionOfProperty	0	USD
	us-gaap	Contribution Of Property ContributionOfProperty	24665000	USD
CY2017Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4282000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4282000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	16943000	USD
CY2018Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12661000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	693000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	656000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	593000	USD
	us-gaap	Depreciation Depreciation	1407000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	497000	USD
	us-gaap	Depreciation Depreciation	1677000	USD
CY2017Q3	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	USD
CY2018Q3	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2567000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	7444000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1095000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2319000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.89
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
CY2017Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1327000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2575000	USD
CY2018Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-795000	USD
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q3	us-gaap	Equity Method Investments EquityMethodInvestments	24665000	USD
CY2017Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2018Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1233000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2458000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	145000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-740000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1328000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2578000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	131000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-795000	USD
CY2017Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2018Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	24884000	USD
CY2017Q3	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	0	USD
CY2018Q3	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-2838000	USD
	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-2838000	USD
CY2017Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	26000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	26000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3659000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12586000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2631000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10075000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	24364000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	22471000	USD
CY2017Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018Q3	us-gaap	Goodwill Transfers GoodwillTransfers	-1893000	USD
CY2017Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	14811000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	14811000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11600000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48482000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28755000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43093000	USD
CY2017Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2018Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2838000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2838000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4282000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4282000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-4282000	USD
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	340000	USD
CY2018Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	342000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1805000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3513000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1094000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2171000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-196000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	573000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-784000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	136000	USD
CY2017Q3	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2018Q3	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-128000	USD
CY2017Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6739000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2018Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-325000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2093000	USD
CY2017Q3	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	744000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	744000	USD
CY2018Q3	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
CY2017Q3	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-133000	USD
CY2018Q3	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2000	USD
CY2017Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-83000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	189000	USD
CY2018Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-109000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1017000	USD
CY2017Q3	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	756000	USD
CY2017Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	42000	USD
CY2018Q3	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	18000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	54688000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	30146000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	237161000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	245418000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14627000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12668000	USD
CY2017Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2018Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61000	USD
CY2018Q3	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-320000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	770000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58647000	USD
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43836000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	76000	USD
	us-gaap	Interest Expense InterestExpense	186000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	104000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	337000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	419000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	435000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55537000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5305000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27116000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24378000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48911000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15680000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38298000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13204000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50791000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-11600000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48482000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-17429000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	3091000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-24473000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-38811000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11600000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48482000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27040000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-46255000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1297000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2199000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3671000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29784000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	19789000	USD
	us-gaap	Operating Expenses OperatingExpenses	58847000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	34013000	USD
	us-gaap	Operating Expenses OperatingExpenses	77144000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12897000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50681000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-32426000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72877000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	358000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-12000	USD
CY2017Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-5843000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-34192000	USD
CY2018Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-24590000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	48025000	USD
CY2018Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	592000	USD
CY2018Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	2520000	USD
CY2018Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	-172000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	2940000	USD
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	538000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7076000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	237000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	911000	USD
CY2017Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2018Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2567000	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	7444000	USD
CY2017Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	49780000	USD
CY2018Q3	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	123489000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	500000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	500000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2144000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1127000	USD
CY2017Q3	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	108000	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	108000	USD
CY2018Q3	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2018Q3	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	66265000	USD
CY2017Q3	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2018Q3	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000	USD
CY2017Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	USD
CY2018Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	435000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1273000	USD
CY2017Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	353000	USD
CY2018Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	0	USD
CY2017Q3	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2018Q3	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2018Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24854000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16813000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12183000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10421000	USD
CY2017Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12001000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15537000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44854000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16566000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46871000	USD
CY2017Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018Q1	us-gaap	Restructuring Charges RestructuringCharges	1621000	USD
CY2018Q2	us-gaap	Restructuring Charges RestructuringCharges	2581000	USD
CY2018Q3	us-gaap	Restructuring Charges RestructuringCharges	-492000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3710000	USD
	us-gaap	Restructuring Costs RestructuringCosts	396000	USD
CY2018Q1	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	1029000	USD
CY2018Q2	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	61000	USD
CY2018Q3	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	-320000	USD
	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	770000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-738070000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-784325000	USD
CY2017Q3	us-gaap	Revenues Revenues	6892000	USD
	us-gaap	Revenues Revenues	8166000	USD
CY2018Q3	us-gaap	Revenues Revenues	1587000	USD
	us-gaap	Revenues Revenues	4267000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	72060000	USD
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	120085000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	66265000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	103000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	735000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	434000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	182473000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	232418000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	238072000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	215272000	USD
CY2017Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2018Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2018Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	770000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54877103	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54612081	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55421504	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55241284	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). To pursue its strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieving profitable operations. The Company's research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company's existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-013909-index-headers.html	Edgar Link	pending
0001628280-18-013909-index.html	Edgar Link	pending
0001628280-18-013909.txt	Edgar Link	pending
0001628280-18-013909-xbrl.zip	Edgar Link	pending
abus-20180930.xml	Edgar Link	completed
abus-20180930.xsd	Edgar Link	pending
abus-20180930_cal.xml	Edgar Link	unprocessable
abus-20180930_def.xml	Edgar Link	unprocessable
abus-20180930_lab.xml	Edgar Link	unprocessable
abus-20180930_pre.xml	Edgar Link	unprocessable
arbutusq32018.htm	Edgar Link	pending
exhibit101execemploymentgp.htm	Edgar Link	pending
exhibit311q32018.htm	Edgar Link	pending
exhibit312q32018.htm	Edgar Link	pending
exhibit31amendmenttoarticl.htm	Edgar Link	pending
exhibit321q32018.htm	Edgar Link	pending
exhibit322q32018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelinea02.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2018 Q4 Form 10-Q Financial Statement

#000162828018013909 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2018 Q4 Form 10-Q Financial Statement

#000162828018013909 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus